Galibra Neuroscience Receives FDA Orphan Drug and Rare Pediatric Disease Designations for SSADH Deficiency Gene Therapy
Galibra Neuroscience has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its SSADH deficiency gene therapy.
Galibra Neuroscience announced it has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration (FDA) for its investigational gene therapy targeting Succinic Semialdehyde Dehydrogenase (SSADH) deficiency.
These designations are crucial for the development of what could be the first disease-modifying therapy for this ultra-rare neurometabolic disorder. SSADH deficiency is an inherited condition that leads to the accumulation of neurotoxic metabolites and causes severe neurological symptoms.
The ODD provides incentives such as market exclusivity for a period after approval and tax credits for certain clinical research costs. The Rare Pediatric Disease Designation may qualify the company for a Priority Review Voucher (PRV), which can be redeemed to expedite the FDA review of a future drug application.
Galibra Neuroscience is advancing its gene therapy towards clinical trials to evaluate its safety and efficacy in pediatric patients with SSADH deficiency.